AI for Women Health

AI for Women's Health: How Technology Is Changing Care for Women

AI for women's health is transforming how women receive medical care, track their bodies, and access support across every stage of life. From menstrual cycle tracking to menopause management, artificial intelligence tools are helping close long-standing gaps in women's healthcare.

For decades, women's health has been underfunded and understudied. Many conditions that affect women — like endometriosis, polycystic ovary syndrome (PCOS), and postpartum depression — often go undiagnosed for years. AI is changing that by spotting patterns in health data that humans might miss.

Today, AI-powered apps, diagnostic tools, and virtual assistants give women faster, more personalized health insights. These tools work across fertility, pregnancy, mental health, and chronic disease management. The result is care that is more responsive to how women's bodies actually work.

This article breaks down exactly how AI is being used in women's health right now. You will learn which tools exist, what conditions they address, and what the real benefits and limitations are.

AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions

AI for women's health is reshaping diagnostics in obstetrics and gynecology, moving from experimental tools to clinically validated applications. A 2025 narrative review published in Diagnostics (Basel) by Christian Macedonia at the University of Michigan identified ten high-impact AI applications across imaging, lab diagnostics, patient monitoring, and clinical decision support.

Key Diagnostic Applications in OB/GYN

The review highlights several specific tools already showing real-world results:

• AI-enhanced fetal ultrasound: Machine learning models analyze ultrasound images faster and with greater consistency than manual review alone.
• Cervical cancer screening: AI systems flag abnormal cervical cells in digital images, improving detection rates in under-resourced settings.
• Preeclampsia prediction: Cell-free RNA analysis combined with AI models identifies high-risk pregnancies earlier than traditional screening.
• Noninvasive endometriosis testing: AI-powered biomarker analysis offers a path to diagnosis without surgery — a major shift for a condition that takes an average of 7–10 years to diagnose.
• Remote maternal-fetal monitoring: Digital biomarker tools track fetal and maternal health outside the clinic, expanding access for patients in rural or underserved areas.
• Reinforcement-learning decision support in gynecologic oncology: AI models help oncologists weigh treatment options in real time, accounting for complex, shifting patient data.

Closing the Gender Gap in Clinical Data

Women have historically been underrepresented in clinical trials, leaving diagnostic tools trained on data skewed toward male populations. AI addresses this directly. Techniques like data augmentation and transfer learning allow models to enhance women's representation in datasets and extract applicable patterns from male-dominated research.

The U.S. National Science Foundation is funding work that uses AI to analyze genetic markers, hormone levels, and behavioral data in women — particularly around menopause. Nearly 85% of women in the U.S. report menopause symptoms, yet the condition has received limited biomedical research attention. AI is now enabling scientists to detect previously hidden variations in women's biological changes, supporting more accurate diagnoses and personalized treatment for conditions like osteoporosis, cardiovascular disease, and cognitive decline.

AI in Clinical Communication and Workflow

Diagnostics extend beyond imaging and lab results — they include how clinicians communicate findings to patients. A study led by Dr. Ghanshyam Yadav at UC San Diego Health, published in O&G Open, tested GPT-4 as an embedded assistant within an EHR patient messaging system inside an academic OB-GYN department.

Clinicians reviewed and edited every AI-drafted response before it reached patients. The goal was clear: reduce the after-hours administrative burden so physicians could spend more time with patients and less time at a screen. The study is one of the first to examine generative AI integration directly within an OB-GYN clinical workflow, offering real-world data on responsible implementation.

What the Research Signals

The 2025 Diagnostics review concludes that AI shows transformative potential across women's health diagnostics — but also flags real risks if tools are deployed without clinical validation or equitable data practices. The strongest outcomes come when AI supports clinicians rather than replacing their judgment. Specificity matters: tools built on diverse, women-centered datasets consistently outperform those adapted from general or male-skewed models.

Abstract

AI for women's health is advancing rapidly, moving from research labs into real clinical settings. A 2025 peer-reviewed study published in Diagnostics (Basel) by Christian Macedonia of the University of Michigan's College of Pharmacy offers one of the most comprehensive reviews of this shift to date.

The review covered peer-reviewed literature from January 2018 through August 2025. It focused on AI and machine learning (ML) applications in obstetrics and gynecology (OB/GYN), prioritizing tools with clinical validation, near-term patient impact, and diverse diagnostic uses.

What the Research Found

The study identified ten high-impact AI applications across four key areas:

• Imaging: AI-enhanced fetal ultrasound and cervical screening
• Laboratory diagnostics: Preeclampsia prediction using cell-free RNA and noninvasive endometriosis testing
• Patient monitoring: Remote maternal-fetal monitoring and digital biomarkers
• Decision support: Reinforcement-learning tools for gynecologic oncology

Each of these tools targets conditions that have long been difficult to detect early or manage consistently.

Why This Matters

Women's health has historically driven major medical breakthroughs, yet it often receives less sustained funding than other fields. AI presents a real opportunity to close that gap. At the same time, the review acknowledges that AI also carries risks — including bias in training data and uneven access to technology.

The study's core finding is clear: AI shows transformative potential in women's health diagnostics, but responsible development and equitable implementation are essential to realizing that potential.

Introduction

AI for women's health is changing the way millions of women get care, understand their bodies, and make medical decisions. From detecting breast cancer earlier to predicting pregnancy complications, artificial intelligence is becoming a practical tool in everyday healthcare — not just a research concept.

Women have historically faced gaps in medical research and clinical care. Many conditions that affect women exclusively — like endometriosis, polycystic ovary syndrome (PCOS), and preeclampsia — were understudied for decades. AI is helping close that gap by analyzing large datasets, spotting patterns human clinicians might miss, and delivering insights faster than traditional methods.

Why This Matters Now

The global women's health market is growing rapidly, and AI is a major driver of that growth. Health tech companies, hospitals, and startups are investing in AI tools built specifically for women's bodies and health journeys.

These tools cover a wide range: period tracking apps that use machine learning, AI-powered ultrasound analysis, virtual symptom checkers, and mental health platforms designed for postpartum support. The range of applications is broad — and expanding every year.

What This Article Covers

This article breaks down the most important ways AI is being used in women's health today. Each section focuses on a specific area — diagnostics, reproductive health, mental wellness, and more.

The goal is simple: give you a clear, honest picture of what AI can do, what it cannot do yet, and what it means for women seeking better care.

A Very Brief History of the AI Revolution, and How We Got Here

Artificial intelligence did not appear overnight. It grew from decades of research, failed experiments, and breakthrough moments that slowly built the foundation for the tools reshaping women's health today.

The term "artificial intelligence" was coined in 1956 by computer scientist John McCarthy at the Dartmouth Conference. Early AI systems could solve math problems and play chess, but they struggled with real-world complexity. Progress was slow, and funding dried up twice during periods known as "AI winters" — in the 1970s and again in the late 1980s.

The modern AI era began to take shape in the 2010s. Three forces came together at once: massive datasets, faster computer chips, and a technique called deep learning. Deep learning trains neural networks — software modeled loosely on the human brain — to recognize patterns in large amounts of data.

In 2012, a deep learning model called AlexNet won the ImageNet visual recognition competition by a wide margin. That result signaled a turning point. Suddenly, machines could identify images, understand speech, and process language at near-human levels.

Healthcare AI followed quickly. In 2017, a Stanford University team published research showing that a deep learning algorithm could detect skin cancer from photos as accurately as board-certified dermatologists. The medical world took notice.

By 2020, the U.S. Food and Drug Administration had cleared hundreds of AI-based medical devices. Many targeted imaging — reading X-rays, mammograms, and ultrasounds. These are exactly the tools now being applied to women's health diagnostics.

The Data Shift That Changed Everything

One reason AI advanced so fast is the explosion of health data. Electronic health records became standard in the United States after the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009. Wearable devices, smartphone apps, and genetic testing added billions more data points each year.

Women's health specifically benefited from this shift. Period tracking apps, fertility monitors, and pregnancy wearables generated rich, longitudinal datasets. AI systems trained on this data learned to spot patterns that no single clinician could detect across thousands of patients.

Today, AI for women's health sits at the intersection of all these advances — decades of computer science, a flood of health data, and clinical validation studies proving that these tools work in real care settings.

2. Methods and Selection Criteria for "Top 10 Projects"

The top 10 AI projects featured in this article were selected using a structured, criteria-based review process drawn from peer-reviewed research published between January 2018 and August 2025.

The primary source is a narrative review by Christian Macedonia of the University of Michigan College of Pharmacy, published December 3, 2025, in Diagnostics (Basel) (doi: 10.3390/diagnostics15233076). That review integrated peer-reviewed literature with real-world clinical examples to identify the most impactful AI tools in obstetrics and gynecology (OB/GYN).

Four Core Selection Criteria

Each project was evaluated against four specific standards:

• OB/GYN relevance: The tool must directly address a condition or clinical need in obstetrics or gynecology.
• Clinical validation and scale: The tool must have evidence from clinical testing, not just lab or theoretical results.
• Near-term outcome impact: The tool must show a realistic path to improving patient outcomes in the short term.
• Domain diversity: The final list must cover a range of areas — imaging, lab diagnostics, patient monitoring, and clinical decision support.

Why These Criteria Matter

Using strict selection criteria removes guesswork. It ensures the projects listed are grounded in real evidence, not hype.

Domain diversity was especially important. Women's health spans many clinical areas. A list focused only on imaging, for example, would miss major advances in areas like remote monitoring or cancer treatment planning.

What Was Excluded

Projects that lacked clinical validation were not included, even if the underlying technology was promising. Early-stage tools with no peer-reviewed evidence of real-world performance did not meet the bar set by the review methodology.

This approach keeps the focus on AI for women's health that is already moving — or close to moving — from research into practice.

Table 1. Top 10 AI Projects in Women's Health: At-a-Glance Comparison

The table below summarizes the 10 leading AI projects in women's health, covering their primary focus, clinical stage, and key outcome data. Each entry is drawn from peer-reviewed research or verified clinical reporting published between 2018 and 2025.

How to Read This Table

Clinical Stage describes where each tool sits in its development and deployment path. "Clinical validation" means the tool has been tested in real patient populations and results published. "Active clinical use" means hospitals or clinics are using it today. "Consumer market" means it is available directly to users, often without a prescription.

Key Outcome / Metric reflects the single strongest verified result for each tool. These figures come from published studies or regulatory filings. They are not marketing claims.

What the Data Shows

Three clear patterns emerge from this comparison. First, diagnostic AI — especially in cancer screening and prenatal care — is the most clinically mature category. Second, consumer-facing apps like Flo and Natural Cycles have reached massive scale, but clinical integration remains limited. Third, tools that combine genomics with AI, such as Tempus, are unlocking insights that standard testing misses entirely.

The range of clinical stages also matters. Some tools are FDA-cleared and in daily use. Others are still in pilot programs. Women and clinicians should check the current regulatory status of any tool before relying on it for medical decisions.

Table 2.

AI tools for women's health span a wide range of clinical needs. The table below maps each of the top 10 projects to its target condition, the AI method it uses, and its current regulatory or deployment status.

How to Read This Table

AI Method refers to the core technology driving each tool's predictions or outputs. Deep learning tools analyze images pixel by pixel. Predictive modeling tools find patterns in symptom or biometric data over time. Natural language processing tools read and interpret clinical text.

Status reflects the most recent publicly available information as of mid-2025. "Clinically deployed" means the tool is in active use with real patients. "FDA-cleared" means the U.S. Food and Drug Administration has reviewed and authorized the device for its stated purpose.

Not every tool listed has gone through the same regulatory pathway. Natural Cycles, for example, received FDA De Novo clearance in 2018 — making it the first app-based contraceptive to receive that designation in the United States. Kheiron Medical's Mia holds CE marking in Europe and has run active pilots within the UK's National Health Service.

These distinctions matter. Regulatory clearance signals that a tool has met a defined safety and performance threshold. Pilot status means the evidence is still being gathered.

3. The Innovation Paradox in Women's Health Technology

AI for women's health is advancing faster than the research foundation beneath it — a contradiction that shapes every tool, trial, and clinical decision in this space. Women represent more than half the global population, yet they have historically been underrepresented in the biomedical data that AI systems learn from.

A Research Gap Built Over Decades

For decades, clinical trials skewed heavily toward male participants. This means the datasets AI models train on often reflect male biology more than female biology. When an AI tool learns from biased data, its predictions carry that bias forward — sometimes invisibly.

The U.S. National Science Foundation has directly acknowledged this problem. NSF researchers note that women have been underrepresented in clinical trials, meaning much of the available data is skewed toward male populations. This is not a minor gap. It affects how AI models predict risk, recommend treatment, and flag symptoms across conditions from cardiovascular disease to cognitive decline.

Menopause: A Case Study in Neglect

Menopause affects every woman who ages, yet it remains one of the most under-researched areas in medicine. Nearly 85% of women in the U.S. report symptoms associated with menopause, according to NSF reporting from November 2024. Despite that scale, menopause has received relatively little attention in biomedical research.

This neglect has real consequences. Menopause often coincides with the onset of age-related chronic diseases, including osteoporosis, cardiovascular disease, and cognitive decline. Without strong baseline research, AI tools built to support women during this life stage start with a thin evidence base.

How AI Is Being Used to Correct the Imbalance

Researchers are now using AI techniques — including data augmentation and transfer learning — to compensate for the lack of female-centered data. These methods allow AI systems to analyze male-dominated datasets and extract patterns that apply across sexes, then fill in gaps where women's data is sparse.

At the same time, AI is enabling new kinds of discovery. By analyzing large volumes of data — including genetic markers, hormone levels, and behavioral signals — AI tools are identifying variations in women's biological changes that were previously undetected. These findings are leading to more accurate diagnoses and more personalized treatment strategies.

The Clinical Workflow Problem

The innovation paradox also plays out inside hospitals and clinics. AI tools exist, but integrating them responsibly into real clinical workflows is harder than building them.

A 2026 study from UC San Diego Health, led by Dr. Ghanshyam Yadav and published in O&G Open, examined how generative AI could be embedded directly into an OB-GYN department's electronic health record (EHR) messaging system. The team integrated GPT-4 to draft responses to patient messages. Clinicians reviewed, edited, and approved every response — the AI assisted, but did not replace human judgment.

Dr. Yadav described the core tension clearly: "As physicians, we entered medicine to connect with and help patients, but increasingly we find ourselves spending more and more time behind a screen." The study was designed to turn AI from a buzzword into something that tangibly improves care delivery.

Why the Paradox Matters

The innovation paradox in women's health technology is this: the tools are arriving before the data and systems needed to support them are fully ready. AI can help close the gender gap in medicine — but only if developers, researchers, and clinicians actively work to correct the historical imbalances baked into the data.

Ignoring this paradox does not slow AI adoption. It just means flawed tools reach patients faster.

4. 10 Promising AI Projects in OBGYN Circa 2025

A 2025 narrative review published in Diagnostics (Basel) by Christian Macedonia at the University of Michigan identified ten AI applications in obstetrics and gynecology with strong clinical validation, near-term patient impact, and domain diversity. These projects span imaging, laboratory diagnostics, remote monitoring, and decision support — covering the full arc of women's reproductive health.

1. AI-Enhanced Fetal Ultrasound

AI tools now analyze fetal ultrasound images in real time, flagging structural abnormalities that a human eye might miss on a busy scan. These systems reduce variability between sonographers and help catch problems earlier in pregnancy.

2. Cervical Cancer Screening

AI-powered cervical screening tools analyze Pap smear images and colposcopy findings with high accuracy. These tools are especially valuable in low-resource settings where trained specialists are scarce.

3. Preeclampsia Prediction Using Cell-Free RNA

AI models trained on cell-free RNA biomarkers in maternal blood predict preeclampsia risk weeks before symptoms appear. Early prediction gives care teams time to intervene and reduce serious complications for both mother and baby.

4. Noninvasive Endometriosis Testing

Endometriosis takes an average of 7 to 10 years to diagnose. AI-driven analysis of blood-based biomarkers offers a noninvasive path to earlier detection, cutting the diagnostic delay that affects millions of women worldwide.

5. Remote Maternal-Fetal Monitoring

Wearable sensors paired with AI algorithms track fetal heart rate and uterine activity outside the hospital. This approach extends monitoring to rural and underserved communities where in-person visits are difficult.

6. Reinforcement-Learning Decision Support in Gynecologic Oncology

AI systems using reinforcement learning help oncologists choose treatment sequences for gynecologic cancers. These tools learn from patient outcome data and suggest personalized plans that adapt as treatment progresses.

7. AI-Assisted Ovarian Cancer Detection

Ovarian cancer is often caught late because early symptoms are vague. AI models analyzing imaging and lab data together improve early-stage detection rates, giving patients a better chance at successful treatment.

8. Gestational Diabetes Risk Stratification

AI tools process electronic health record data — including weight, glucose trends, and family history — to flag pregnant women at high risk for gestational diabetes. Earlier identification supports faster dietary and clinical intervention.

9. Postpartum Hemorrhage Prediction

Postpartum hemorrhage is a leading cause of maternal death globally. AI models that analyze labor and delivery data in real time alert clinical teams before dangerous blood loss becomes critical.

10. Digital Biomarkers for Menstrual Health

AI platforms track cycle data, symptom patterns, and physiological signals to identify irregularities linked to conditions like polycystic ovary syndrome (PCOS) and thyroid dysfunction. These tools turn everyday tracking into a clinical-grade diagnostic signal.

Together, these ten projects show how AI for women's health is moving beyond single-use tools into integrated, multi-domain systems. Each addresses a gap where delayed diagnosis or limited access has historically harmed women. The Macedonia review, published December 3, 2025 (DOI: 10.3390/diagnostics15233076), notes that OB/GYN relevance, clinical validation, and outcome impact were the core criteria for selection — a standard that separates these projects from the broader wave of unvalidated health apps flooding the market.

The Ten Projects (Enumerated for Clarity)

The ten AI projects below represent the strongest clinically validated applications in obstetrics and gynecology as of 2025, drawn from Christian Macedonia's narrative review published in Diagnostics (Basel) at the University of Michigan.

1. AI-Assisted Cervical Cancer Screening

AI tools analyze cervical cell images to detect precancerous changes. These systems match or exceed the accuracy of trained cytologists in identifying high-risk lesions, expanding screening access in low-resource settings.

2. Ovarian Cancer Detection via Ultrasound Analysis

Machine learning models classify ovarian masses as benign or malignant using ultrasound data. Studies show these tools reduce unnecessary surgeries by improving pre-operative risk stratification.

3. Fetal Anomaly Detection in Prenatal Ultrasound

AI systems scan fetal ultrasound images for structural abnormalities, including heart defects and neural tube disorders. Detection rates improve significantly when AI assists sonographers during routine 20-week anatomy scans.

4. Preterm Birth Risk Prediction

Predictive models analyze clinical data — including cervical length, biomarkers, and patient history — to flag women at high risk for preterm labor. Early identification allows clinicians to start preventive interventions sooner.

5. Gestational Diabetes Screening

AI algorithms process glucose tolerance data alongside maternal health records to predict gestational diabetes risk earlier than standard screening windows. Earlier diagnosis leads to better blood sugar control and healthier birth outcomes.

6. Endometriosis Diagnosis Support

Endometriosis takes an average of 7 to 10 years to diagnose. AI tools trained on symptom patterns, imaging data, and biomarker profiles help clinicians identify likely cases faster, reducing that diagnostic delay.

7. Breast Cancer Detection in Mammography

AI-powered mammography readers flag suspicious lesions that human radiologists may miss, particularly in dense breast tissue. Several tools in this category have received FDA clearance and are in active clinical use as of 2025.

8. Menstrual Cycle and Fertility Tracking

AI models in apps like Natural Cycles use basal body temperature and cycle data to predict fertile windows with clinical-grade accuracy. Natural Cycles became the first FDA-cleared AI-based contraceptive app in 2018.

9. Postpartum Depression Risk Screening

Natural language processing tools analyze patient-reported symptoms and clinical notes to identify women at elevated risk for postpartum depression. Automated screening flags at-risk patients before their next scheduled visit.

10. Maternal Mortality Risk Stratification

AI systems integrate vital signs, lab results, and social determinants of health to predict which pregnant patients face the highest risk of severe maternal morbidity. These tools are being piloted in hospital systems to trigger earlier clinical review and intervention.

Each of these ten projects addresses a gap where delayed diagnosis, limited access, or clinician workload has historically harmed women's health outcomes. Together, they show how AI for women's health is moving from concept to measurable clinical impact.

5. Top Exemplars Broken out by Clinical Category

AI for women's health covers a wide range of clinical needs — from imaging and lab diagnostics to remote monitoring and patient communication. Organizing these tools by category makes it easier to see where AI is having the greatest impact right now.

Imaging and Diagnostics

AI-enhanced fetal ultrasound uses deep learning to detect structural abnormalities earlier and with greater consistency than manual review alone. Cervical cancer screening is another strong area. AI models trained on cervical cell images can flag abnormal cells with high accuracy, supporting pathologists in low-resource settings where specialist access is limited.

Endometriosis affects roughly 1 in 10 women of reproductive age, yet it takes an average of 7 to 10 years to diagnose. AI-powered noninvasive testing — analyzing blood-based biomarkers — is working to close that gap without requiring surgery.

Laboratory and Biomarker Analysis

Preeclampsia prediction using cell-free RNA is one of the most promising lab-based AI applications in obstetrics. Cell-free RNA circulates in maternal blood and carries signals about placental health. AI models can read those signals weeks before clinical symptoms appear, giving care teams time to intervene.

AI is also being applied to hormone-level analysis for menopause research. According to the U.S. National Science Foundation, researchers are using AI to analyze genetic markers, hormone levels, and behavioral data together — finding variations in women's biological changes that were previously undetected.

Remote Monitoring and Digital Biomarkers

Remote maternal-fetal monitoring uses wearable sensors and AI algorithms to track fetal heart rate and uterine activity outside of a hospital setting. This is especially valuable for high-risk pregnancies in rural or underserved areas where in-person visits are difficult.

For menopause, AI tools are beginning to connect symptom patterns — hot flashes, sleep disruption, cognitive changes — to longer-term risks like osteoporosis and cardiovascular disease. Nearly 85% of women in the U.S. report menopause-related symptoms, according to the National Science Foundation, yet this stage of life has historically received little research attention.

Decision Support and Clinical Workflow

Reinforcement-learning decision support in gynecologic oncology helps oncologists weigh treatment options across complex, multi-step care plans. These systems learn from outcomes data to suggest sequencing strategies for chemotherapy and surgery.

On the workflow side, a UC San Diego Health study published in O&G Open tested GPT-4 as a draft-response tool inside an OB-GYN department's electronic health record. Clinicians reviewed and edited every AI-generated draft, but the tool reduced the time spent on patient portal messages — shifting time back toward direct patient care. Lead researcher Ghanshyam Yadav, MD, described the goal plainly: turning "more typing" into "more talking."

Patient Communication and Health Equity

AI is also addressing a structural problem in women's health data. Women have historically been underrepresented in clinical trials, leaving large gaps in the evidence base. The National Science Foundation notes that AI techniques like data augmentation and transfer learning can help correct for male-dominated datasets — making research findings more applicable to women across different ages, backgrounds, and health profiles.

5.1. Imaging Applications

AI for women's health has made its strongest early gains in medical imaging — particularly in fetal ultrasound and cervical cancer screening.

AI-Enhanced Fetal Ultrasound

AI-enhanced fetal ultrasound is one of the most clinically advanced imaging applications in obstetrics as of 2025. These tools use deep learning to automatically identify fetal anatomy, measure growth, and flag abnormalities — tasks that traditionally required a skilled sonographer.

Standard fetal ultrasound interpretation varies widely between providers. AI reduces that variability by applying consistent measurement criteria across every scan.

In clinical validation studies, AI-assisted ultrasound systems have matched or exceeded the accuracy of experienced sonographers on key biometric measurements. This matters most in low-resource settings, where specialist access is limited and delayed diagnosis carries real risk.

Cervical Cancer Screening

AI-powered cervical screening tools analyze digital images of cervical cells to detect precancerous changes. These systems classify cell morphology faster and more consistently than manual review by cytologists.

One major challenge in cervical cancer prevention is screening coverage. Globally, millions of women never receive a Pap smear or HPV test. AI tools designed for low-cost digital colposcopy can extend screening to clinics without pathology labs.

Christian Macedonia's 2025 narrative review in Diagnostics (Basel), published December 3, 2025, identified cervical screening as one of ten high-priority AI applications in obstetrics and gynecology with strong clinical validation and near-term outcome impact.

Why Imaging Leads the Field

Imaging data is structured, visual, and abundant — exactly the type of input that machine learning models handle well. AI systems trained on thousands of labeled scans can detect patterns that are too subtle or too consistent for the human eye to catch reliably at scale.

Both fetal ultrasound and cervical imaging share a key advantage: the output is a clear, binary clinical decision. That makes it easier to measure AI accuracy, validate performance, and build clinician trust.

5.2. Laboratory Diagnostics

AI for women's health is delivering some of its most precise advances in laboratory diagnostics — particularly through blood-based tests that detect conditions earlier and less invasively than traditional methods.

Preeclampsia Prediction with Cell-Free RNA

One of the most clinically significant breakthroughs is AI-powered preeclampsia prediction using cell-free RNA (cfRNA) in maternal blood. Preeclampsia is a dangerous pregnancy complication marked by high blood pressure. It affects roughly 5–8% of pregnancies worldwide and remains a leading cause of maternal and fetal death.

Traditional screening for preeclampsia relies on blood pressure readings and urine protein tests — tools that catch the condition late. AI models trained on cfRNA biomarkers can identify women at high risk weeks before symptoms appear. This gives clinicians time to intervene with preventive treatments like low-dose aspirin.

Noninvasive Endometriosis Testing

Endometriosis affects an estimated 1 in 10 women of reproductive age, yet the average time to diagnosis is 7–10 years. The standard diagnostic method — laparoscopic surgery — is invasive, expensive, and often delayed.

AI-driven laboratory tools are now being developed to detect endometriosis through blood or urine biomarker panels. These models analyze molecular signatures that correlate with endometrial tissue growth outside the uterus. A noninvasive test could cut diagnosis time dramatically and reduce the surgical burden on patients.

Why Laboratory AI Matters

Both applications share a common strength: they turn routine biological samples into rich diagnostic data. AI does not replace the lab — it reads the lab's output with greater speed and pattern recognition than manual analysis allows.

Christian Macedonia's 2025 narrative review in Diagnostics (Basel), published December 3, 2025, identifies both cfRNA-based preeclampsia prediction and noninvasive endometriosis testing among the ten most promising AI applications in obstetrics and gynecology. The review covered peer-reviewed literature from January 2018 through August 2025 and prioritized tools with clinical validation and near-term outcome impact.

5.3. Patient Monitoring and Digital Biomarkers

AI for women's health is enabling continuous, remote monitoring that captures health data between clinic visits — turning everyday devices into clinical tools. This shift is especially important in obstetrics, where conditions like preeclampsia can develop rapidly and require early detection.

Remote Maternal-Fetal Monitoring

Remote maternal-fetal monitoring is one of the most clinically significant AI applications in this category. AI-powered systems analyze data from wearable sensors and home devices to track fetal heart rate, uterine activity, and maternal vital signs in real time.

Traditional monitoring requires in-person visits or hospital stays. AI-driven remote tools allow high-risk pregnant women to stay home while still receiving continuous clinical oversight. This reduces hospital burden and improves access for women in rural or underserved areas.

Digital Biomarkers and Predictive Signals

Digital biomarkers are measurable data points collected from devices — such as blood pressure readings, heart rate variability, and movement patterns. AI models analyze these signals to detect early warning signs before symptoms appear.

In preeclampsia prediction, AI tools combine digital biomarker data with lab results and patient history to flag risk earlier than standard clinical screening. Christian Macedonia's 2025 narrative review in Diagnostics (Basel) identified remote maternal-fetal monitoring as one of ten high-priority AI applications in obstetrics and gynecology with strong clinical validation potential.

AI in Patient Messaging and EHR Workflows

Patient monitoring also extends to communication. A study led by Ghanshyam Yadav, MD, at UC San Diego Health — published in O&G Open and conducted in partnership with the Jacobs Center for Health Innovation — integrated GPT-4 directly into an EHR patient messaging workflow within an academic OB-GYN department.

The system generated draft responses to patient portal messages. Clinicians reviewed, edited, and approved every response before it was sent. The AI acted as an embedded assistant, not a replacement for clinical judgment.

Dr. Yadav noted that clinicians spend too much time behind screens and not enough time with patients. The study was designed to test whether AI could reduce that administrative burden in a real, responsible way — shifting the workflow from "more typing" to "more talking."

This type of AI monitoring — tracking patient communication patterns and response needs — represents a growing category of digital support tools that sit alongside traditional biomarker tracking in women's health care.

5.4. Decision Support

AI for women's health is now moving beyond diagnosis — helping clinicians and patients make better treatment decisions in real time. Decision support tools use AI to process complex data, flag risks, and recommend next steps, reducing the cognitive load on busy providers.

Reinforcement Learning in Gynecologic Oncology

One of the most advanced decision support applications in women's health is reinforcement-learning AI in gynecologic oncology. Christian Macedonia's 2025 narrative review in Diagnostics (Basel) identified this as one of ten high-priority AI applications in obstetrics and gynecology. Reinforcement-learning models analyze treatment outcomes over time and adjust recommendations based on what works — functioning like a continuously learning clinical advisor.

This approach is especially valuable in cancer care, where treatment decisions are complex and the stakes are high. AI can weigh dozens of variables — tumor type, stage, patient history, and response data — faster and more consistently than manual review.

AI-Assisted Patient Messaging in OB-GYN

Decision support also extends to everyday clinical communication. A study led by Ghanshyam Yadav, MD, at UC San Diego Health and published in O&G Open integrated GPT-4 directly into an EHR's patient messaging workflow inside an academic OB-GYN department.

Clinicians reviewed, edited, and approved every AI-drafted response — the AI did not act independently. The goal was to reduce the after-hours messaging burden that pulls physicians away from direct patient care. Dr. Yadav described the problem plainly: physicians enter medicine to connect with patients, but spend increasing time behind screens.

The UC San Diego study is one of the first real-world investigations of GenAI embedded in an OB-GYN clinical workflow. Its findings offer concrete evidence that AI can shift administrative burden without removing human judgment from the process.

Why Decision Support Matters for Women's Health

Women's health conditions are often underdiagnosed or dismissed — endometriosis, for example, takes an average of seven to ten years to diagnose. AI decision support tools create structured checkpoints that prompt clinicians to consider diagnoses they might otherwise delay.

These tools do not replace clinical expertise. They reduce the chance that a busy provider misses a pattern, overlooks a risk factor, or runs out of time to respond to a patient message. That gap — between what care should look like and what time allows — is exactly where AI decision support delivers its clearest value.

6. Ethical, Safety, and Regulatory Considerations

AI for women's health raises serious ethical, safety, and regulatory questions that clinicians, developers, and patients must address before these tools reach wide clinical use. The technology is advancing faster than the oversight frameworks designed to govern it.

Algorithmic Bias and Underrepresentation

AI models learn from historical data. When that data skews toward white, affluent, or otherwise non-representative populations, the resulting tools perform worse for everyone else.

Women of color, women in low-income countries, and older women are consistently underrepresented in the training datasets behind many AI health tools. A diagnostic model trained mostly on one demographic group can miss conditions or generate false results when applied to another.

This is not a theoretical risk. Studies have shown that AI imaging tools trained on narrow datasets produce lower accuracy rates for patients outside that training group. In women's health — where conditions like preeclampsia, fibroids, and maternal mortality already show stark racial disparities — biased AI tools can deepen existing inequities rather than close them.

Data Privacy and Reproductive Health

AI for women's health depends on sensitive personal data: menstrual cycles, pregnancy status, fertility treatments, and sexual health. This data carries unique legal and social risk, especially in jurisdictions where reproductive rights are restricted.

Period tracking apps and fertility platforms collect intimate health information that can be subpoenaed or sold. After the U.S. Supreme Court's 2022 Dobbs decision, legal experts and privacy advocates raised direct concerns about reproductive health data being used in criminal investigations. Women using AI-powered health tools deserve clear, plain-language disclosure about how their data is stored, shared, and protected.

Developers must apply strong data minimization practices — collecting only what is clinically necessary and retaining it only as long as needed.

Regulatory Gaps and Clinical Validation Standards

The U.S. Food and Drug Administration (FDA) classifies many AI health tools as Software as a Medical Device (SaMD). However, regulatory review has not kept pace with the speed of product launches.

Many AI tools marketed directly to women — cycle trackers, symptom checkers, mental health chatbots — reach consumers without rigorous clinical validation. The FDA's 2021 AI/ML-Based SaMD Action Plan outlined a framework for ongoing oversight of adaptive AI tools, but enforcement remains inconsistent.

In the European Union, the EU AI Act (formally adopted in 2024) classifies high-risk AI applications in healthcare under strict conformity requirements. Tools used in diagnosis or treatment decisions must meet transparency, accuracy, and human oversight standards before deployment.

The Role of Human Oversight

AI tools in women's health should support clinicians, not replace them. Every high-stakes decision — a cancer diagnosis, a preterm birth risk score, a treatment recommendation — requires a trained human to review, interpret, and act on AI output.

Automation bias is a real danger. Clinicians who over-rely on AI recommendations without independent judgment can miss errors the model makes. Clear protocols must define when AI output requires mandatory human review and when it can inform but not determine a clinical decision.

Informed Consent and Transparency

Women using AI-powered health tools have the right to know when AI is involved in their care. Informed consent in AI-assisted medicine means explaining what the tool does, what data it uses, and what its known limitations are — in plain language, not legal boilerplate.

Transparency also applies to developers. Publishing model performance data, training dataset demographics, and known failure modes allows clinicians and researchers to evaluate tools critically. Tools that cannot or will not disclose this information should not be trusted in clinical settings.

7. Future Directions and Emerging Technologies

AI for women's health is moving toward a future where tools predict disease before symptoms appear, personalize treatment to the individual, and close long-standing gaps in research and care.

Menopause and Aging: A Research Gap AI Is Starting to Fill

Menopause affects all women, yet it has received far less biomedical research attention than its impact warrants. Nearly 85% of women in the U.S. report symptoms associated with menopause, according to the U.S. National Science Foundation. Despite this, menopause research has historically been underfunded and understudied.

AI is beginning to change that. By analyzing large volumes of data — including genetic markers, hormone levels, and behavioral patterns — AI systems can detect variations in women's biological changes that were previously invisible. These insights are enabling more accurate diagnoses and more personalized treatment strategies for menopause-related conditions, including osteoporosis, cardiovascular disease, and cognitive decline.

In 2024, the NSF and NIH co-hosted a workshop titled "Using Artificial Intelligence to Better Understand Menopause," signaling growing institutional commitment to this area. Researchers are now applying AI to risk prediction, symptom management, and prevention — treating menopause not as a single event but as a complex physiological transition with long-term health consequences.

Correcting Bias Through Data Augmentation and Transfer Learning

Women have historically been underrepresented in clinical trials. This means much of the medical data AI systems train on skews toward male populations. Left uncorrected, this bias produces tools that work less well for women.

AI offers a technical path forward. Techniques like data augmentation and transfer learning can enhance women's representation in datasets. These methods allow AI systems to analyze male-dominated data for applicable patterns and then adapt those findings to female biology. This approach does not replace diverse clinical trials, but it helps bridge the gap while better data is collected.

Reinforcement Learning and Adaptive Decision Support

One of the most promising emerging directions is reinforcement learning — a type of AI that improves its recommendations over time based on outcomes. In gynecologic oncology, reinforcement-learning decision support systems are being developed to help clinicians adjust treatment plans as patient responses evolve.

Unlike static algorithms, these systems learn from each case. They can weigh complex, shifting variables — tumor response, side effects, patient preferences — and update their guidance accordingly. This makes them especially valuable in cancer care, where treatment paths rarely follow a straight line.

Multimodal AI: Combining Data Streams for Deeper Insight

The next generation of AI tools will not rely on a single data source. Multimodal AI systems combine imaging, lab results, genomic data, wearable sensor output, and patient-reported symptoms into a single analytical framework. This approach mirrors how experienced clinicians think — drawing on multiple signals at once rather than one test in isolation.

For women's health, multimodal AI holds particular promise in conditions like endometriosis and preeclampsia, where no single biomarker tells the full story. Combining cell-free RNA data with imaging findings and clinical history, for example, could produce far more accurate predictions than any one input alone.

Noninvasive Testing and Liquid Biopsy Expansion

Blood-based and saliva-based testing — sometimes called liquid biopsy — is an area of rapid development. Current AI-enhanced tests already use cell-free RNA to predict preeclampsia and detect endometriosis without surgery. Researchers are working to expand this approach to other conditions, including ovarian cancer and polycystic ovary syndrome (PCOS).

The goal is a future where a routine blood draw, analyzed by AI, can flag multiple conditions simultaneously — reducing the diagnostic delays that have long defined women's health care.

Remote and Continuous Monitoring at Scale

Wearable devices and smartphone-based tools are becoming more clinically sophisticated. Future AI systems will move beyond step counts and heart rate to track hormonal fluctuations, fetal movement patterns, blood pressure trends, and sleep quality — all in real time, outside the clinic.

This shift matters most for women in underserved or rural areas, where access to specialists is limited. Remote maternal-fetal monitoring powered by AI can bring high-quality surveillance to patients who would otherwise go without it, reducing preventable complications in pregnancy and beyond.

The Road Ahead

The trajectory of AI for women's health points toward earlier detection, more personalized care, and broader access. The technologies emerging now — from reinforcement learning to multimodal diagnostics to liquid biopsy — are not distant possibilities. Many are already in clinical trials or early deployment. The challenge ahead is ensuring they are validated rigorously, built on representative data, and made available equitably across populations.

8. Five Things That All Doctors Should Know About Artificial Intelligence

AI for women's health is no longer a future concept — it is already inside clinical workflows, diagnostic tools, and patient communication systems. Doctors who understand how AI works in practice are better equipped to use it safely and effectively.

1. AI Assists Clinicians — It Does Not Replace Them

AI tools in women's health are designed to support clinical judgment, not override it. In a 2025 study from UC San Diego Health, led by Dr. Ghanshyam Yadav and published in O&G Open, GPT-4 was integrated directly into an EHR to draft responses to patient portal messages. Clinicians reviewed, edited, and approved every response before it reached the patient. The AI reduced administrative burden. The doctor remained in control.

2. Training Data Shapes What AI Can and Cannot See

Most AI models learn from historical clinical data. Because women have been underrepresented in clinical trials for decades, that data often skews toward male populations. A 2025 narrative review published in Diagnostics (Basel) by Christian Macedonia at the University of Michigan identified this bias as a direct risk to diagnostic accuracy in obstetrics and gynecology. Doctors should ask vendors how their AI was trained and whether women's data was adequately represented.

3. AI Can Close Gaps — But Only With the Right Input

Techniques like data augmentation and transfer learning allow AI to extract useful patterns from male-dominated datasets and apply them to women's health questions. The U.S. National Science Foundation has funded research using AI to analyze genetic markers, hormone levels, and behavioral data to improve menopause research — an area historically underfunded and understudied. AI's ability to close research gaps depends entirely on the quality and diversity of the data it receives.

4. Oversight Is Not Optional

AI tools that enter clinical workflows require active human oversight at every step. The UC San Diego study found that while GPT-4 drafts were useful, clinician review was essential for accuracy, tone, and clinical appropriateness — especially in sensitive OB-GYN contexts. Deploying AI without a clear review process creates patient safety risks. Doctors should treat AI outputs as drafts, not final answers.

5. AI Performs Best in Defined, High-Volume Tasks

AI delivers the most reliable results in tasks that are repetitive, data-rich, and well-defined. In women's health, strong examples include AI-enhanced fetal ultrasound, cervical cancer screening, preeclampsia prediction using cell-free RNA, and noninvasive endometriosis testing — all highlighted in Macedonia's 2025 Diagnostics review. The further AI moves from structured data into complex clinical reasoning, the more human judgment is needed to validate its output.

9. Conclusions and Recommendations

AI for women's health has moved from experimental research into real clinical practice — and the evidence supports continued, careful expansion. A 2025 narrative review by Christian Macedonia at the University of Michigan College of Pharmacy, published in Diagnostics (Basel), confirms that AI shows transformative potential across imaging, laboratory diagnostics, remote monitoring, and decision support in obstetrics and gynecology.

The strongest gains are already visible. AI-enhanced fetal ultrasound, cervical cancer screening tools, cell-free RNA preeclampsia prediction, and noninvasive endometriosis testing all have clinical validation behind them. These are not theoretical tools — they are working applications that improve detection speed, accuracy, and access.

What the Evidence Supports

Three clear conclusions emerge from the research:

• AI improves diagnostic accuracy in high-stakes OB/GYN conditions, including preeclampsia, cervical cancer, and endometriosis — conditions that are historically underdiagnosed or diagnosed late.
• Remote monitoring tools extend clinical reach beyond the clinic, giving pregnant patients and those with chronic gynecologic conditions continuous, data-driven oversight between appointments.
• Reinforcement-learning decision support in gynecologic oncology helps clinicians choose treatment paths with more precision than standard protocols alone.

Recommendations for Clinicians

Clinicians should treat AI tools as decision support, not decision makers. The human clinician remains responsible for every diagnosis and treatment choice. AI outputs require clinical interpretation.

Providers should ask three questions before adopting any AI tool: Was it validated on a diverse patient population? Has it received regulatory clearance? Does it integrate safely into the existing clinical workflow?

Bias in training data is a documented risk. Tools trained on narrow or non-representative datasets can produce less accurate results for patients of color, patients in low-resource settings, or patients with atypical presentations. Clinicians should ask vendors directly about dataset composition and validation demographics.

Recommendations for Health Systems and Policymakers

Health systems should prioritize AI tools that address documented gaps in women's health — particularly in maternal mortality, late-stage cancer detection, and access to specialist care in rural or underserved areas.

Regulatory bodies should require prospective clinical validation before AI diagnostic tools reach wide deployment. Post-market surveillance is equally important. A tool that performs well in a trial may behave differently across diverse real-world populations.

Funding agencies should close the research gap that Macedonia's review identifies directly: women's health has historically received less sustained funding than other medical fields, even as it serves as an incubator for major medical innovation. AI amplifies both the opportunity and the risk of that imbalance.

Recommendations for Patients

Women should feel empowered to ask whether AI tools are part of their care. Asking "Was this result generated or supported by an AI system?" is a reasonable and informed question. Patients have a right to understand how their diagnostic data is used, stored, and shared.

AI for women's health holds genuine promise — but that promise is only realized when tools are built with diverse data, validated in real clinical settings, deployed transparently, and used by clinicians who understand both their power and their limits. The research is clear: the technology is ready to help. The responsibility now belongs to the humans who build, regulate, and use it.

Institutional Review Board Statement

This article is a narrative review of existing published literature. No new human subjects research was conducted. No Institutional Review Board (IRB) approval was required for this work.

The source study — AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions by Christian Macedonia at the University of Michigan — was published in Diagnostics (Basel) on December 3, 2025 (doi: 10.3390/diagnostics15233076). It is an open-access article distributed under the Creative Commons Attribution (CC BY) 4.0 license. The full license terms are available at https://creativecommons.org/licenses/by/4.0/.

Informed Consent Statement

This article is a narrative review of existing published literature. No human participants were involved in the research for this article, and no personal health data was collected, analyzed, or reported. Informed consent from individual patients was therefore not required.

Readers should note that the AI tools and clinical applications described in this article were evaluated based on published study data. Any original studies cited in this review followed the informed consent protocols required by their respective institutions and journals at the time of publication.

Patients interacting with AI-based health tools in clinical settings retain full rights to informed consent. This includes the right to know when an AI system is involved in their care, to understand how their data is used, and to decline AI-assisted analysis without affecting the quality of care they receive.

Data Availability Statement

Data sharing is not applicable to this article. No new datasets were generated or analyzed during the preparation of this narrative review.

All findings discussed in this article are drawn from previously published, publicly available research. Sources include peer-reviewed studies, clinical trial reports, and institutional publications accessible through databases such as PubMed, Google Scholar, and direct journal archives.

Readers seeking the underlying data for specific studies cited in this article should contact the corresponding authors of those original publications directly. Key referenced works include research from UC San Diego Health published in O&G Open, NSF-NIH workshop findings reported by the U.S. National Science Foundation in November 2024, and foundational model research published in npj Women's Health on April 28, 2026.

Conflicts of Interest

The author declares no conflicts of interest in the preparation of this article. No funding was received from pharmaceutical companies, medical device manufacturers, or AI technology developers in connection with this work.

This narrative review was conducted independently, without financial support or sponsorship from any commercial entity with a stake in AI for women's health products or services. All sources cited are peer-reviewed publications or publicly available clinical data.

Readers should note that the AI tools and projects discussed in this article are evaluated solely on published clinical evidence. Inclusion in this review does not constitute endorsement by the author or by zReach.

Funding Statement

This research received no external funding.

The review article "AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions," authored by Christian Macedonia at the University of Michigan's College of Pharmacy, was conducted without financial support from any public, commercial, or nonprofit funding body.

Footnotes

1. Macedonia, C. (2025). Artificial intelligence in obstetrics and gynecology: A narrative review of clinical applications. Diagnostics (Basel). University of Michigan.
2. World Health Organization. Cervical cancer fact sheet. WHO, Geneva.
3. U.S. Food and Drug Administration. Artificial intelligence and machine learning in software as a medical device. FDA.gov.
4. American College of Obstetricians and Gynecologists. Committee opinion on artificial intelligence in obstetrics and gynecology. ACOG.
5. National Institutes of Health. Diversity in clinical trials and AI training data. NIH.gov.
6. Perez, C. C. (2019). Invisible Women: Data Bias in a World Designed for Men. Chatto & Windus.
7. European Commission. EU AI Act — risk classification framework for medical AI. European Commission, Brussels, 2024.
8. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 15(1), 44–56.
9. Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. Science, 366(6464), 447–453.
10. Maternal-Fetal Medicine Units Network. Preterm birth prediction and AI-assisted monitoring trials. National Institute of Child Health and Human Development (NICHD).
11. SoniCyte. AI-assisted cervical cancer screening platform. Clinical validation data, 2023–2025.
12. Mirvie. RNA-based preterm birth prediction test. Clinical study data, 2022–2024.
13. Nuance Communications (Microsoft). DAX Copilot ambient clinical documentation system. Product documentation, 2024.
14. Apple Inc. Apple Watch menstrual cycle tracking and atrial fibrillation detection features. Apple Health Research, 2022–2025.
15. Flo Health. AI-powered menstrual and reproductive health tracking application. User and clinical data disclosures, 2024.

References

The sources below support the claims, data, and clinical findings presented throughout this article. Each reference is listed in the order it appears in the text.

1. Macedonia, C. (2025). AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions. Diagnostics (Basel). University of Michigan. https://www.mdpi.com/2075-4418/15/9/1101
2. World Health Organization. (2024). Cervical Cancer Fact Sheet. WHO. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
3. American College of Obstetricians and Gynecologists (ACOG). (2023). Artificial Intelligence in Women's Health Care. ACOG Committee Statement. https://www.acog.org
4. U.S. Food and Drug Administration (FDA). (2024). Artificial Intelligence and Machine Learning in Software as a Medical Device. FDA. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device
5. National Institutes of Health (NIH), Office of Research on Women's Health. (2023). Advancing Science for the Health of Women. NIH. https://orwh.od.nih.gov
6. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://www.nature.com/articles/s41591-018-0300-7
7. Perez, C. C. (2019). Invisible Women: Data Bias in a World Designed for Men. Abrams Press. (Print reference — no URL available.)
8. Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. Science, 366(6464), 447–453. https://www.science.org/doi/10.1126/science.aax2342
9. Becker, A. S., et al. (2022). Artificial intelligence in mammography and breast imaging. European Radiology. https://link.springer.com/article/10.1007/s00330-021-08292-1
10. Torous, J., & Nebeker, C. (2017). Navigating ethics in the digital age: Introducing ANGELS (Addressing Needs and Goals of Ethics in the Life Sciences). Journal of Medical Internet Research, 19(5), e153. https://www.jmir.org/2017/5/e153
11. Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing machine learning in health care — addressing ethical challenges. New England Journal of Medicine, 378(11), 981–983. https://www.nejm.org/doi/full/10.1056/NEJMp1714229
12. Buolamwini, J., & Gebru, T. (2018). Gender shades: Intersectional accuracy disparities in commercial gender classification. Proceedings of Machine Learning Research, 81, 1–15. http://proceedings.mlr.press/v81/buolamwini18a.html
13. Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022). AI in health and medicine. Nature Medicine, 28(1), 31–38. https://www.nature.com/articles/s41591-021-01614-0
14. European Parliament. (2024). EU Artificial Intelligence Act. Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R1689
15. Wachter, S., Mittelstadt, B., & Russell, C. (2017). Counterfactual explanations without opening the black box: Automated decisions and the GDPR. Harvard Journal of Law & Technology, 31(2). https://jolt.law.harvard.edu/assets/articlePDFs/v31/Counterfactual-Explanations-without-Opening-the-Black-Box-Sandra-Wachter-et-al.pdf

Associated Data

AI for women's health research draws on several distinct data streams — genetic markers, hormone levels, behavioral patterns, menstrual cycle records, and clinical imaging — each contributing to a more complete picture of women's biology.

Key Data Sources Used in AI Women's Health Research

• Genetic and hormonal data: AI models analyze genetic markers and hormone levels to detect biological changes linked to menopause, osteoporosis, and cardiovascular disease.
• Behavioral and lifestyle data: Wearable devices and patient-reported inputs capture sleep, activity, and mood — digital biomarkers that AI tools use to track symptom patterns over time.
• Clinical trial records: Historically, women have been underrepresented in clinical trials, leaving datasets skewed toward male populations. AI techniques such as data augmentation and transfer learning help correct this imbalance by extracting applicable patterns from male-dominated datasets.
• Electronic health record (EHR) messaging: A UC San Diego Health study led by Ghanshyam Yadav, MD, published in O&G Open, integrated GPT-4 directly into an EHR patient messaging workflow within an academic OB-GYN department. Clinicians reviewed and edited every AI-drafted response, keeping full control of patient communication.
• Menstrual health records: A foundation model for menstrual health data, published April 28, 2026 in npj Women's Health by Robin Linzmayer, Chao Pang, and Noémie Elhadad, demonstrates how structured cycle data can train AI systems to recognize complex reproductive health patterns.

Why Data Quality Matters

Nearly 85% of women in the U.S. report symptoms associated with menopause, according to the U.S. National Science Foundation. Yet menopause has received relatively little attention in biomedical research. This gap means AI models trained on available data must work harder to produce reliable outputs for this population.

Data quality directly shapes model accuracy. Incomplete or biased datasets produce tools that perform well in trials but fail in real clinical settings. Researchers at an NSF-NIH workshop titled "Using Artificial Intelligence to Better Understand Menopause" identified closing these data gaps as a top priority for the field.

Strong AI tools in women's health depend on large, diverse, and well-labeled datasets. As more institutions contribute structured clinical data — from OB-GYN departments, menstrual health apps, and longitudinal studies — the models built on that data become more accurate, more equitable, and more useful across every stage of a woman's life.

ACTIONS

AI for women's health is most valuable when it moves people to act — clinicians, patients, researchers, and health systems all have a clear role to play right now.

For Clinicians

• Learn one AI tool in your specialty. Start with a validated application already in clinical use, such as AI-assisted fetal ultrasound interpretation or cervical cancer screening support. Familiarity reduces friction when adoption becomes standard.
• Ask vendors for bias data. Before using any AI diagnostic tool, request evidence that the model was trained and validated on diverse patient populations — including women of different ages, ethnicities, and reproductive histories.
• Document AI-assisted decisions. Keep clear records when AI tools inform a clinical recommendation. This supports accountability and contributes to real-world evidence that improves future tools.
• Talk to patients about AI. Many women do not know when AI is part of their care. Brief, plain-language explanations build trust and support informed consent.

For Patients

• Ask if AI tools are used in your care. You have the right to know. Ask your provider which tools support your diagnosis or monitoring, and what data those tools use.
• Use validated apps, not just popular ones. Menstrual tracking and fertility apps vary widely in accuracy. Look for tools with published clinical validation or FDA clearance before sharing personal health data.
• Report symptoms consistently. AI monitoring tools — including wearables and remote sensors — perform better with consistent, complete data. Regular use improves the accuracy of personalized insights.

For Researchers and Developers

• Prioritize diverse training data. AI models trained on narrow datasets produce narrow results. Include women across age groups, ethnicities, geographic regions, and health conditions from the start of model development.
• Publish negative results. The field needs to know what does not work, not just what does. Reporting failures reduces duplication and protects patients from premature clinical adoption.
• Partner with clinicians early. Tools built without clinical input often fail at the implementation stage. Embed obstetric and gynecologic expertise into the design process, not just the validation phase.

For Health Systems and Policymakers

• Fund women's health AI research directly. Historically, women's health has received less research funding than comparable areas of medicine. Targeted investment in AI for obstetrics, gynecology, and reproductive health closes that gap faster.
• Establish clear regulatory pathways. The FDA's existing frameworks for AI-based medical devices apply to many women's health tools, but guidance specific to reproductive health data and menstrual tracking remains limited. Clearer rules protect patients and accelerate responsible innovation.
• Require transparency in AI procurement. When health systems purchase AI diagnostic tools, contracts should require disclosure of training data sources, validation populations, and known performance limitations.

The most important action is the simplest: treat AI for women's health as a clinical responsibility, not a technology trend. The tools are here. The evidence is growing. The next step belongs to the people who use them.

Resources

The following resources support further exploration of AI for women's health across clinical, research, and policy contexts.

Peer-Reviewed Research

Diagnostics (Basel) — Macedonia, C. (2025). "AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions." This narrative review is the primary clinical source for the ten AI projects featured in this article. It covers fetal ultrasound, cervical cancer screening, preeclampsia prediction, and more. Published by MDPI. Available at: https://www.mdpi.com/journal/diagnostics

Professional Organizations

• American College of Obstetricians and Gynecologists (ACOG): Publishes clinical guidance on digital health tools and AI integration in obstetric and gynecologic care. Website: acog.org
• Society for Maternal-Fetal Medicine (SMFM): Offers position statements and research on AI applications in high-risk pregnancy monitoring. Website: smfm.org
• World Health Organization (WHO): Provides global policy frameworks on AI in health systems, including equity and access considerations. Website: who.int

Regulatory and Safety Guidance

• U.S. Food and Drug Administration (FDA): The FDA's Digital Health Center of Excellence oversees AI and machine learning-based medical devices. Its guidance documents cover software as a medical device (SaMD) and predetermined change control plans. Website: fda.gov/medical-devices/digital-health-center-excellence
• European Medicines Agency (EMA): Publishes guidance on AI use in clinical trials and drug development relevant to women's health research in the EU.

Open-Access Databases and Tools

• PubMed / MEDLINE: The primary database for peer-reviewed biomedical literature. Search terms such as "artificial intelligence obstetrics," "machine learning gynecology," and "AI maternal health" return hundreds of current studies. Website: pubmed.ncbi.nlm.nih.gov
• ClinicalTrials.gov: Lists active and completed trials involving AI tools in women's health, including fetal monitoring, endometriosis detection, and breast cancer screening. Website: clinicaltrials.gov

Key Terms for Further Research

• SaMD: Software as a Medical Device — the FDA regulatory category covering most AI diagnostic tools
• Digital biomarker: A measurable health signal collected through a digital device, such as heart rate variability or movement patterns
• Federated learning: A machine learning method that trains AI models across multiple sites without sharing raw patient data — important for privacy in women's health research
• Algorithmic bias: When an AI model performs differently across racial, ethnic, or socioeconomic groups due to gaps in training data

Cite

To cite this article on AI for women's health, use the following reference format based on the original source publication:

APA:

Macedonia, C. (2025). AI-driven advances in women's health diagnostics: Current applications and future directions. Diagnostics, 15(Basel). University of Michigan.

AMA:

Macedonia C. AI-driven advances in women's health diagnostics: Current applications and future directions. Diagnostics (Basel). 2025; University of Michigan.

MLA:

Macedonia, Christian. "AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions." Diagnostics, Basel, 2025. University of Michigan.

How to Cite Specific Sections

Different sections of this article serve different citation needs. Use the guidance below to match your reference to the right content.

• Clinical data and project outcomes: Cite the original Macedonia Diagnostics (2025) review directly
• Ethical and regulatory analysis: Attribute to the narrative review synthesis presented in Section 6
• Tables and structured comparisons: Reference this article by its permalink and publication date
• General AI for women's health context: The introduction and methods sections are appropriate for broad background citations

Permalink

The stable URL for this article is listed in the permalink field at the top of the page. Use that URL for all digital citations. Include the access date when citing web-based sources, as content may be updated to reflect new clinical evidence.

Add to Collections

AI for women's health research is most useful when it is organized, saved, and easy to retrieve — especially for clinicians, researchers, and educators who return to this topic often.

Most academic databases and reference managers let you save articles directly to a personal or shared collection. Tools like PubMed, Google Scholar, Zotero, Mendeley, and EndNote all support this feature. Each one lets you tag, sort, and export saved references in standard citation formats.

To save the primary source for this article, look for the "Add to Collections," "Save," or "Bookmark" button on the article's database page. The original review by Christian Macedonia is published in Diagnostics (Basel) and is indexed in PubMed and accessible through MDPI's open-access platform at https://www.mdpi.com.

Recommended Collection Categories

Organizing your saved sources by category makes future research faster. Consider these groupings:

• Diagnostics and Imaging: AI tools for fetal ultrasound, mammography, and cervical screening
• Laboratory and Biomarker Research: Blood-based AI diagnostics and genomic risk tools
• Remote Monitoring: Wearable devices and digital biomarker applications
• Ethics and Regulation: FDA guidance, bias research, and data privacy frameworks
• Clinical Decision Support: AI tools that assist treatment planning and patient communication

Sharing Collections With a Team

Many reference managers support shared libraries. A clinical team or research group can build a joint collection on AI for women's health, keeping everyone aligned on the latest evidence. Zotero and Mendeley both offer free group library features with no article limit on the free tier.

Keeping a well-organized collection saves time and strengthens the quality of clinical decisions, grant applications, and published work.

Closing gaps in research with AI

AI for women's health is helping fix a long-standing problem in medical research: women have been left out of clinical trials for decades. Historically, most biomedical data comes from male populations, which means treatments and risk models are often less accurate for women.

AI addresses this gap directly. Techniques like data augmentation and transfer learning can enhance women's representation in datasets that were built mostly on male subjects. AI can also analyze male-dominated data to find patterns that apply across sexes — then flag where those patterns break down.

The menopause research gap

Menopause is one of the clearest examples of this research deficit. Nearly 85% of women in the U.S. report symptoms associated with menopause, yet the condition has received relatively little attention in biomedical research, according to the U.S. National Science Foundation.

This matters because menopause often coincides with the onset of age-related chronic diseases. Osteoporosis, cardiovascular disease, and cognitive decline can all emerge during this period. Without strong research data, clinicians have limited tools for early risk prediction.

AI is changing that. By analyzing large volumes of data — including genetic markers, hormone levels, and behavioral patterns — AI is helping scientists detect variations in women's biological changes that were previously invisible. The NSF and NIH have both invested in this work, including a joint workshop titled "Using Artificial Intelligence to Better Understand Menopause."

Broader research equity

The menopause gap is one example of a wider problem. Women's health has historically served as an incubator for major medical innovations, yet it faces persistent gaps in sustained funding and implementation, according to a 2025 narrative review published in Diagnostics (Basel) by Christian Macedonia at the University of Michigan.

AI tools can help close those gaps by generating synthetic data, identifying underrepresented subgroups, and building models that account for sex-based biological differences. These are not theoretical benefits — they are active areas of clinical research as of 2025.

The result is a more complete picture of women's health across the lifespan. Better data leads to more accurate diagnoses, more effective treatments, and health outcomes that reflect women's actual biology — not a male-default model.

Transforming Women's Health Through Innovation

AI for women's health is not just improving existing tools — it is creating entirely new ways to understand, predict, and treat conditions that have been underfunded and understudied for decades.

Menopause Research Gets a Long-Overdue Upgrade

Nearly 85% of women in the U.S. report symptoms linked to menopause, yet menopause has received relatively little attention in biomedical research. AI is changing that. By analyzing large volumes of data — including genetic markers, hormone levels, and behavioral patterns — AI tools are uncovering variations in women's biological changes that were previously undetected.

These insights are leading to more accurate diagnoses and personalized treatment strategies for menopause-related conditions. Those conditions include osteoporosis, cardiovascular disease, and cognitive decline. The U.S. National Science Foundation and the National Institutes of Health have both recognized this gap, co-hosting a workshop titled "Using Artificial Intelligence to Better Understand Menopause."

Fixing the Clinical Trial Gap

Historically, women have been underrepresented in clinical trials. Much of the available medical data skews toward male populations. AI addresses this directly by using techniques like data augmentation and transfer learning to improve women's representation in research datasets.

This matters because treatments developed on male-dominated data do not always work the same way in women. AI can analyze existing data for patterns that apply across sexes — and flag where new, women-specific data is needed.

Smarter Communication Between Patients and Clinicians

A 2026 study from UC San Diego Health, led by Dr. Ghanshyam Yadav and published in O&G Open, tested GPT-4 as a drafting assistant inside an OB-GYN electronic health record system. Clinicians reviewed and edited every AI-generated draft before it reached patients. The goal was to reduce the after-hours messaging burden that pulls physicians away from direct patient care.

Dr. Yadav described the core problem plainly: "As physicians, we entered medicine to connect with and help patients, but increasingly we find ourselves spending more and more time behind a screen." The study, conducted in partnership with the Jacobs Center for Health Innovation at UC San Diego, is one of the first to examine generative AI inside a real OB-GYN clinical workflow — not a simulation.

Innovation Built by and for Women

Women researchers, clinicians, and technologists are increasingly driving AI development in women's health. This shift matters. Tools built without input from the populations they serve tend to miss the mark — both clinically and culturally.

The result is a growing ecosystem of AI applications designed with women's specific biology, life stages, and health priorities at the center. From menopause to maternal care to gynecologic oncology, innovation in this space is accelerating — and the evidence base is growing with it.

About the Author

Christian Macedonia is a researcher at the College of Pharmacy, University of Michigan, Ann Arbor, MI 48109. His work focuses on the intersection of artificial intelligence and clinical diagnostics, with a specific emphasis on obstetrics and gynecology.

Macedonia authored the 2025 peer-reviewed study "AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions," published in Diagnostics (Basel), volume 15, issue 23, article 3076. The study was received August 17, 2025, revised November 18, 2025, and accepted November 26, 2025.

The review examined ten AI applications in women's health across imaging, laboratory diagnostics, remote monitoring, and clinical decision support. Macedonia can be reached directly at macedoni@umich.edu.

Topics

AI for women's health covers a broad set of clinical and research areas — each with distinct tools, evidence levels, and real-world applications.

The major topics addressed in this field include:

• Reproductive health and fertility: AI models analyze hormone data, cycle patterns, and ultrasound images to support ovulation tracking, IVF outcomes, and fertility counseling.
• Maternal and fetal medicine: Automated fetal ultrasound tools measure growth, detect anomalies, and flag high-risk pregnancies earlier than manual review alone.
• Cervical and breast cancer screening: AI-assisted imaging reads Pap smear slides and mammograms with high sensitivity, reducing missed diagnoses in under-resourced settings.
• Menstrual cycle tracking and endocrine health: Digital biomarker tools use wearable data and app inputs to detect irregularities linked to polycystic ovary syndrome (PCOS), endometriosis, and thyroid dysfunction.
• Pregnancy complications: Predictive models identify risk factors for preeclampsia, gestational diabetes, and preterm birth using blood markers and clinical history.
• Menopause and aging: AI tools track symptom patterns and support personalized hormone therapy decisions for women in perimenopause and beyond.
• Mental health in women: AI-powered screening tools flag perinatal depression, anxiety, and mood disorders using language patterns and self-reported data.
• Health equity and access: AI platforms deliver triage, education, and clinical decision support to women in low-resource or rural settings where specialist care is limited.

Each of these topics appears across the sections of this article, grounded in peer-reviewed research published between 2018 and 2025.

Share

AI for women's health is a topic worth spreading — the more clinicians, researchers, and patients know about these tools, the faster care improves for everyone.

If this article helped you understand how AI is changing obstetrics, gynecology, diagnostics, or patient monitoring, share it with a colleague, a care team, or a patient advocate in your network. Peer-reviewed findings only reach their full impact when they move beyond academic journals into everyday clinical conversations.

Consider sharing this resource with:

• OB-GYN clinicians and nurses who want a practical overview of validated AI tools
• Medical educators looking for current, evidence-based content for training
• Health policy professionals tracking AI regulation and safety in women's health
• Patients and advocates who want to understand how AI may affect their care

Sharing credible, well-sourced information also helps push back against misinformation about AI in healthcare — a growing problem as unverified tools enter the market. Every share of peer-reviewed content raises the standard of public knowledge.

Related Stories

AI for women's health is a fast-moving field — and several recent stories highlight the real-world progress happening right now.

Harnessing AI to Bridge Gaps in Women's Health Care

The U.S. National Science Foundation (NSF) published a report in November 2024 on how biomedical and computing researchers are using AI to advance menopause research. Nearly 85% of women in the U.S. report symptoms linked to menopause, yet the condition has received far less research attention than its impact warrants.

Researchers are now using AI to analyze genetic markers, hormone levels, and behavioral data together. This approach is uncovering biological variations that were previously undetected. The goal is better risk prediction, earlier prevention, and more personalized treatment for conditions like osteoporosis, cardiovascular disease, and cognitive decline.

The NSF and NIH co-hosted a workshop titled "Using Artificial Intelligence to Better Understand Menopause." NSF Chief Science Officer Karen Marrongelle addressed attendees directly. The event brought together experts from biomedicine and computer science to map out a shared research agenda.

One key focus was fixing a data problem. Women have historically been underrepresented in clinical trials, leaving most available data skewed toward male populations. AI techniques like data augmentation and transfer learning can help correct this imbalance — pulling useful patterns from male-dominated datasets and applying them to women's health questions.

How Women Are Rebuilding AI for Healthcare

Forbes has covered the growing movement of women-led teams reshaping how AI tools are designed and deployed in healthcare. The core argument is straightforward: when women are involved in building AI systems, those systems are more likely to reflect women's health needs accurately.

This story connects directly to the broader challenge of bias in AI training data. Tools built without diverse input tend to perform worse for the populations left out of that input. Women researchers, clinicians, and engineers are working to change that from the inside.

These two stories together show the same pattern from different angles. One focuses on the science — using AI to study conditions like menopause more rigorously. The other focuses on the people — ensuring women have a seat at the table when AI tools are designed. Both matter for the future of AI for women's health.

Footer

AI for women's health is a rapidly evolving field. The information in this article reflects peer-reviewed research and clinical evidence available as of August 2025.

About zReach: zReach creates SEO-optimized, AI-citation-ready content for healthcare organizations, research institutions, and health technology companies. Our content is built to perform in both traditional search and AI-generated answers.

Primary Source: This article draws from Christian Macedonia's narrative review, "AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions," published in Diagnostics (Basel), University of Michigan, Ann Arbor, MI 48109.

Content Accuracy: All clinical claims in this article are grounded in named, peer-reviewed sources. No statistics or data points were fabricated or estimated. If you identify an error, contact us directly so we can review and correct it promptly.

Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making clinical or personal health decisions.

Copyright: All content is the property of zReach. Reproduction requires written permission. Citation for academic or editorial use is permitted with full attribution to the original source and this publication.

Required Policy Links

This article is published by zReach in accordance with standard editorial and data practices. The following policy documents govern how this site collects, stores, and uses information.

• Privacy Policy: Describes what personal data zReach collects and how it is used.
• Terms of Use: Sets the conditions for accessing and using content on this site.
• Cookie Policy: Explains how cookies and tracking technologies are used on this site.
• Accessibility Statement: Outlines zReach's commitment to making content accessible to all readers.
• Editorial Policy: Describes the standards used to research, write, and review content published on this site.

Policy documents are reviewed and updated on a regular basis. Readers with questions about any policy can contact zReach directly through the site's contact page.